TY - JOUR
T1 - Prolonged resolution of hemophagocytic lymphohistiocytosis following myeloablative chemotherapy and subsequent autologous peripheral blood stem cell transplantation
AU - Ohga, S.
AU - Nomura, A.
AU - Kai, T.
AU - Matsuzaki, A.
AU - Inaba, S.
AU - Suda, M.
AU - Ueda, K.
N1 - Funding Information:
The English used in this manuscript was revised by Miss K Miller (Royal English Language Centre, Fukuoka, Japan). This work was supported in part by a grant from the Fukuoka Cancer Society, and a grant-in-aid for the encouragement of young scientists from the Ministry of Education Science and Culture of Japan.
Copyright:
Copyright 2018 Elsevier B.V., All rights reserved.
PY - 1997/3/2
Y1 - 1997/3/2
N2 - A 30-month-old boy with hemophagocytic lymphohistiocytosis (HLH) received an autologous peripheral blood stem cell transplant (PBSCT) following high-dose chemotherapy. He presented with hemophagocytic syndrome (HPS) at 6 months of age, but relapsed despite the repeated administration of prednisolone, VP-16, cyclosporin A (CsA), and other cytotoxic agents. PBSC were obtained using combination chemotherapy with etoposide (VP16, 450 mg/m2), doxorubicin (70 mg/m2), vincristine (2 mg/m2) and cyclophosphamide (CY, 1200 mg/m2). 2.7 x 105/kg CFU-GM PBSC were transplanted after similar high-dose VP16 preconditioning used for allogeneic BMT for HLH. The boy continues to remain in complete remission 30 months after PBSCT while receiving low-dose PSL/CsA therapy. High-dose chemotherapy followed by PBSCT may be an optional therapeutic approach for patients with HLH.
AB - A 30-month-old boy with hemophagocytic lymphohistiocytosis (HLH) received an autologous peripheral blood stem cell transplant (PBSCT) following high-dose chemotherapy. He presented with hemophagocytic syndrome (HPS) at 6 months of age, but relapsed despite the repeated administration of prednisolone, VP-16, cyclosporin A (CsA), and other cytotoxic agents. PBSC were obtained using combination chemotherapy with etoposide (VP16, 450 mg/m2), doxorubicin (70 mg/m2), vincristine (2 mg/m2) and cyclophosphamide (CY, 1200 mg/m2). 2.7 x 105/kg CFU-GM PBSC were transplanted after similar high-dose VP16 preconditioning used for allogeneic BMT for HLH. The boy continues to remain in complete remission 30 months after PBSCT while receiving low-dose PSL/CsA therapy. High-dose chemotherapy followed by PBSCT may be an optional therapeutic approach for patients with HLH.
UR - http://www.scopus.com/inward/record.url?scp=0030940995&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0030940995&partnerID=8YFLogxK
U2 - 10.1038/sj.bmt.1700702
DO - 10.1038/sj.bmt.1700702
M3 - Article
C2 - 9085745
AN - SCOPUS:0030940995
VL - 19
SP - 633
EP - 635
JO - Bone Marrow Transplantation
JF - Bone Marrow Transplantation
SN - 0268-3369
IS - 6
ER -